Across TCGA pan-cancer cohorts, MIR101-2 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MIR101-2’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where MIR101-2 RNA is repressed in tumor relative to normal tissue. In most cancer types MIR101-2 is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.

BRCA, LUSC, and PRAD are the cancer types where MIR101-2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MIR101-2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	All	−0.160	.013	4	view →
LUSC	All	II,III,IV	−0.199	.009	2	view →
PRAD	All	All	+0.140	.039	2	view →
CHOL	Female	All	−0.943	.003	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MIR101-2 RNA expression & survival · all MIR101-2 data types